ClinicalTrials.Veeva
Menu

Find clinical trials for Multiple Myeloma in New York, NY

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Plasma Cell Cancer
Lymphoma
Hematologic Cancer
Cancer
Leukemia
Smoldering Multiple Myeloma
Non-Hodgkin Lymphoma

Multiple Myeloma trials near New York, NY, USA:

Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma

of three drugs called lenalidomide, subcutaneous (injection under the skin) bortezomib, and dexamethasone (RVD) as a possible treatment for multiple...

Active, not recruiting
Multiple Myeloma
Drug: Dexamethasone
Procedure: Stem Cell Mobilization

Phase 2

Dana-Farber Cancer Institute
Dana-Farber Cancer Institute

Morristown, New Jersey, United States and 7 other locations

in combination with dexamethasone in subjects with newly diagnosed multiple myeloma followed by treatment with a combination of dru...

Active, not recruiting
Multiple Myeloma
Drug: carfilzomib
Drug: Dexamethasone

Phase 2

Weill Cornell Medicine (WCM)
Weill Cornell Medicine (WCM)

New York, New York, United States

multicenter, dose-escalation study of STI-6129 administered intravenously once in a 4-week cycle in subjects with relapsed or refractory multiple...

Active, not recruiting
Multiple Myeloma
Biological: STI-6129

Phase 1, Phase 2

Sorrento Therapeutics
Sorrento Therapeutics

New York, New York, United States and 2 other locations

The purpose of this study is to evaluate three daratumumab dose schedules in participants with Smoldering Multiple Myeloma....

Active, not recruiting
Multiple Myeloma
Drug: daratumumab

Phase 2

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

New York, New York, United States and 56 other locations

and safety of bb2121 in participants with relapsed and refractory multiple myeloma (RRMM) (Cohort 1), in participants with RRMM who ...

Enrolling
Multiple Myeloma
Biological: bb2121
Drug: Talquetamab

Phase 2

Celgene
Celgene

New York, New York, United States and 25 other locations

(DRd) to that of lenalidomide and dexamethasone (Rd), in terms of progression-free survival in participants with relapsed or refractory multiple...

Active, not recruiting
Multiple Myeloma
Drug: Daratumumab
Drug: Lenalidomide

Phase 3

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

New York, New York, United States and 145 other locations

This is a first in human, phase 1, multicenter, open-label study to determine the safety and tolerability of IGM-2644 as a single agent in participan...

Enrolling
Multiple Myeloma
Drug: IGM-2644

Phase 1

IGM Biosciences

New York, New York, United States and 4 other locations

The purpose of this study is to evaluate the safety and preliminary efficacy of CC-92480 in combination with standard treatments.

Active, not recruiting
Multiple Myeloma
Drug: Carfilzomib
Drug: CC-92480

Phase 1, Phase 2

Celgene
Celgene

Hackensack, New Jersey, United States and 48 other locations

This is a Phase I, first-in-human (FIH), open-label, non-randomized, multi-center study to explore the safety, tolerability, pharmacokinetics and pre...

Enrolling
Multiple Myeloma
Drug: NMS-03597812
Drug: NMS-03597812 + dexamethasone

Phase 1

Nerviano Medical Sciences

New York, New York, United States and 5 other locations

The purpose of this study is to evaluate the safety and preliminary efficacy of CC-95266 in participants with relapsed and/or refractory multiple...

Active, not recruiting
Multiple Myeloma
Drug: Fludarabine
Drug: Bendamustine

Phase 1

Juno Therapeutics

New York, New York, United States and 9 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems